Live Breaking News & Updates on Psychiatry Psychology

Stay updated with breaking news from Psychiatry psychology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Psychedelic psilocybin in magic mushrooms outperformed leading depression treatment


Psychedelic psilocybin in magic mushrooms outperformed leading depression treatment
Psilocybin appeared to treat depression more quickly, for longer and with few side effects than antidepressant escitalopram.
Updated
Subscribe
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
The psychedelic drug found in magic mushrooms has outperformed one of the leading treatments for depression during a scientific study.
The research suggested it may be at least as effective as a leading antidepressant medication in a therapeutic setting, ....

United Kingdom , City Of , Anthony Cleare , Robin Carhart Harris , David Nutt , Edmondj Safra , King College London , Institute Of Psychiatry Psychology , Neuropsychopharmacology At Imperial College London , Psychedelic Research , Imperial College London , Edmondj Safra Chair , New England Journal , Compass Pathways , Item Quick Inventory , Depressive Symptomatology , Psychiatry Psychology , College London , Magic Mushrooms , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ராபின் கார்ஹார்ட் ஹாரிஸ் , டேவிட் நட் , கிங் கல்லூரி லண்டன் , நிறுவனம் ஆஃப் மனநல மருத்துவம் உளவியல் , சைகடெலிக் ஆராய்ச்சி ,

Magic mushrooms perform 'at least as well' as the leading antidepressant in new trial


The psychedelic compound found in magic mushrooms may be at least as effective as a leading antidepressant medication in a therapeutic setting, a new study suggests.
Researchers compared the therapeutic potential of psilocybin – found in the mushrooms – with a six-week course of the antidepressant escitalopram in 59 people with moderate to severe depression.
They found that, while depression scores were reduced in both groups, the reductions occurred more quickly in the psilocybin group and were greater in magnitude.
However, they warned that the main comparison between psilocybin and the antidepressant was not statistically significant.
They said larger trials with more patients over a longer period are needed to show if the compound can perform as well as, or more effectively than, an established antidepressant. ....

United States , United Kingdom , City Of , Anthony Cleare , David Nutt , Edmondj Safra , Robin Carhart Harris , Albert Hofmann , King College London , Friedrich Schiller University Jena , Institute Of Psychiatry Psychology , American Chemical Society , Neuropsychopharmacology At Imperial College London , Drugs Act , Psychedelic Research , Imperial College London , Edmondj Safra Chair , New England Journal , Compass Pathways , Item Quick Inventory , Depressive Symptomatology , Psychiatry Psychology , College London , American Chemical , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் ,